Health News Roundup: Explainer-How climate change is making the world sick; US FDA gives second approval to Eli Lilly's drug for type of blood cancer and more

The spike in illness in the country where COVID emerged in late 2019 attracted the spotlight when the World Health Organization sought information last week, citing a report on clusters of undiagnosed pneumonia in children. EU watchdog seeks more data from GLP-1 drugmakers on suicidal thoughts The EU's drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Novo Nordisk's popular therapies Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them.

Following is a summary of current health news briefs.

Explainer-How climate change is making the world sick

Heat stress. Lung damage from wildfire smoke. The spread of disease-carrying mosquitoes into new regions as temperatures rise. These are just a few of the ways that public health has been impacted and compounded by climate change - a focus for the first time ever at the annual U.N. climate summit COP28.

US FDA gives second approval to Eli Lilly's drug for type of blood cancer

Eli Lilly said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer. The company said the health regulator gave the new approval to the drug for the treatment of chronic lymphocytic leukemia (CLL), a type of cancer in which the bone marrow makes too many of certain white blood cells.

US FDA says BD recalling infusion pumps due to compatibility issues

The U.S. Food and Drug Administration (FDA) said on Friday that Becton Dickinson is recalling its Alaris infusion pumps due to compatibility issues with Cardinal Health's Monoject syringes. The health regulator said Alaris pumps are validated for use with Monoject syringes. However, the dimensions for Monoject syringes have recently changed while rebranding the syringes from Covidien Monoject to Cardinal Health Monoject.

AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT

Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday. The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said. It did not say what kind of cancer they plan to target.

China's respiratory illness rise due to known pathogens -official

China's surge in respiratory illness is caused by known pathogens and there is no sign of new infectious diseases, a health official said on Saturday as the country faces its first full winter since lifting strict COVID-19 restrictions. The spike in illness in the country where COVID emerged in late 2019 attracted the spotlight when the World Health Organization sought information last week, citing a report on clusters of undiagnosed pneumonia in children.

EU watchdog seeks more data from GLP-1 drugmakers on suicidal thoughts

The EU's drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Novo Nordisk's popular therapies Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them. "While at this point no conclusion can be drawn on a causal association, there are several issues that still need to be clarified," the European Medicines Agency (EMA) said in a statement on Friday.

Pfizer drops twice-daily version of obesity pill over side effects

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting, and its shares fell 5%. Pfizer has a once-daily version of the weight-loss pill still in the development. It hopes a change in the drug's release mechanism can reduce side effects, but early data on the new formulation will not be available until the first half of next year.

US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy

Some leading U.S. obesity specialists say they expect Eli Lilly’s powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s popular Wegovy as they belong to the same class of medicines. The views of the five doctors, all senior physicians practicing obesity medicine at top universities and hospitals, indicate that Novo's drug is not likely to have a significant edge based on its heart benefits, even though it will be years before Lilly produces similar cardiovascular data. Both medicines are GLP-1 agonists, a class originally designed to treat type 2 diabetes.